OmniAb and Lilly Enter Ion Channel Collaboration; Near-Term Financial Impact Minimal

What happened

OmniAb announced a global collaboration and license agreement with Eli Lilly for a new ion channel program, leveraging its discovery technology and screening expertise. The company, which licenses antibody discovery platforms to pharma and biotech, generates revenue from license fees, milestones, services, and royalties, but management has consistently warned that such revenue is lumpy and partner-driven. This deal adds Lilly to OmniAb's roster of 107 active partners and 407 active programs, but no financial terms were disclosed, making the near-term revenue contribution uncertain. OmniAb's recent financials show FY2025 revenue of $18.7 million, down from $26.4 million in 2024, with 2026 guidance of $25–30 million and a planned cash burn to $30–35 million by year-end. While the collaboration validates OmniAb's expansion into ion channels, the stock at $1.85 continues to face skepticism until the company demonstrates scalable recurring revenue from xPloration or milestone-bearing clinical progress.

Implication

Adding Lilly, a top-tier pharma, enhances OmniAb's credibility and may attract additional partners, but the lack of financial details limits immediate valuation impact. Historically, OmniAb's partner additions have not directly translated to revenue, as management explicitly states that active partners and programs do not correlate with current revenues. The key near-term catalysts remain xPloration instrument placements (target: >$1.0 million quarterly revenue with at least three installs by Q3 2026) and partner clinical events like Merck KGaA's M9140 Phase III initiation. If the Lilly program progresses to milestones, it could contribute future revenue, but timelines in ion channels are long and unpredictable. Therefore, investors should maintain a wait-and-see approach, focusing on evidence of revenue conversion rather than partnership announcements alone.

Thesis delta

The Lilly collaboration introduces a new high-quality partner in ion channels, which marginally extends OmniAb's platform reach. However, it does not address the core issue of unproven revenue conversion from KPI growth, nor does it alter the near-term cash burn and dilution risk. The thesis remains unchanged: wait for evidence of xPloration recurring revenue or milestone-bearing partner progress before becoming constructive.